Skip to main content

Table 1 Clinical characterization of the study population

From: Local heterogeneity of normal lung parenchyma and small airways disease are associated with COPD severity and progression

 

Non-COPD

COPD

Variable

GOLD 0

PRISm

GOLD 1

GOLD 2

GOLD 3

GOLD 4

Participants (N)

3867

1088

699

1732

1041

529

Age (yrs)

56.7 (8.36)

57.1 (8.20)

61.6 (8.96)

62.6 (8.86)

64.3 (8.27)

64.1 (7.53)

Sex (M/F)

2048/1819

496/592

399/300

933/799

604/437

314/215

BMI (kg/cm2)

29.0 (5.79)

31.9 (7.31)

27.1 (4.89)

28.7 (6.06)

28.1 (6.33)

25.3 (5.56)

Smoking (Pack-Years)

37.2 (20.0)

42.6 (24.2)

45.0 (24.4)

50.9 (26.8)

55.1 (27.1)

56.7 (28.7)

FEV1% Predicted (%)

97.4 (11.4)

70.6 (7.89)

90.8 (8.70)

65.0 (8.51)

40.2 (5.69)

22.6 (4.84)

FEV1/FVC

0.79 (0.05)

0.77 (0.05)

0.65 (0.04)

0.58 (0.08)

0.44 (0.09)

0.31 (0.07)

FEF25 − 75(L/s)

2.81 (1.00)

1.79 (0.66)

1.31 (0.50)

0.80 (0.35)

0.39 (0.16)

0.21 (0.08)

PRMNorm(%)

61.7 (13.0)

53.8 (14.6)

56.9 (12.1)

49.1 (13.5)

33.0 (12.5)

21.1 (9.13)

PRMfSAD(%)

9.90 (9.31)

8.88 (8.25)

17.0 (10.8)

21.3 (11.5)

30.9 (11.0)

36.0 (8.94)

PRMEmph(%)

0.80 (1.42)

0.73 (2.29)

3.00 (3.49)

5.40 (6.95)

14.7 (12.2)

26.0 (14.0)

PRMPD(%)

26.3 (12.8)

35.8 (16.4)

20.8 (8.44)

22.2 (9.04)

19.6 (9.29)

15.7 (5.43)

  1. Notes Participant characteristics of the entire study population separated in subsets of those with (FEV1/FVC < 0.7) and without (FEV1/FVC ≥ 0.7) COPD. Values are displayed as mean (standard deviation). GOLD, Global Initiative for Chronic Obstructive Lung Disease; PRISm, preserved ratio impaired spirometry; GOLD 0, at-risk smokers with normal spirometry; BMI, body mass index; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; FEF25 − 75, forced mid-expiratory flow; PRM, parametric response map; Norm, Normal; fSAD, functional small airways disease; Emph, emphysema; PD, parenchymal disease
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us